Skip to main content

Wegovy FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 17, 2023.

FDA Approved: Yes (First approved June 4, 2021)
Brand name: Wegovy
Generic name: semaglutide
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Weight Loss (Obesity/Overweight)

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an adjunct to diet and exercise for chronic weight management.

 

 

 

Development timeline for Wegovy

DateArticle
Nov 11, 2023Wegovy (semaglutide) Injection 2.4 mg Cardiovascular Outcomes Data Presented at the American Heart Association Scientific Sessions and Simultaneously Published in the New England Journal of Medicine
Aug  8, 2023Novo Nordisk A/S: Semaglutide 2.4 mg Reduces the Risk of Major Adverse Cardiovascular Events by 20% in Adults with Overweight or Obesity in the SELECT Trial
Dec 23, 2022Approval FDA Approves Once-Weekly Wegovy injection for the Treatment of Obesity in Teens Aged 12 Years and Older
Jun  4, 2021Approval FDA Approves Wegovy (semaglutide) to Treat Adults with Obesity
Mar 23, 2021Adults with Obesity Treated with Semaglutide 2.4 mg Achieved and Maintained a Significant Amount of Weight Loss in a 68-Week Trial

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.